<DOC>
	<DOCNO>NCT03005119</DOCNO>
	<brief_summary>A Phase II , double-blind , randomize , placebocontrolled , parallel-group study . Sixty ( 60 ) MS patient enrol . PTL201 dose titrate one-week period reach MTD participant . The MTD administer three week thereafter . Participants demonstrate response treatment continue self administer daily PTL201 treatment placebo , additional four week . Participants fill daily diary .</brief_summary>
	<brief_title>Evaluation Safety , Tolerability , Efficacy Orally Administered PTL201 MS Patients With Spasticity-related Symptoms</brief_title>
	<detailed_description>A Phase II , double-blind , randomize , placebocontrolled , parallel-group study . Spasticity one common disable symptoms MS , Cannabinoids reduce pain spasticity MS patient . PTL201 capsule contain 5 mg THC 5 mg cannabidiol ( CBD ) . PTL201 dose titrate one-week period reach maximum tolerate dose ( MTD ) participant ( participant tell may receive placebo active treatment , although treatment active ) . The MTD self administer three week thereafter . Participants demonstrate response treatment continue self administer daily PTL201 treatment placebo , additional four week . Participants keep daily diary .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Dronabinol</mesh_term>
	<criteria>1 . Patient ( male female ) , age 1865 year 2 . Definite diagnosis MS , accord McDonald 2010 criterion , least six month prior enrollment , MS associate spasticity least 3 month prior enrollment 1 . Patients suffer moderate tosevere MSassociated spasticity ( ≥4 sNRS ) , adequate response traditional antispastic medication 2 . EDSS score : 4 ≤ EDSS ≤ 6 ; functional motor score ≥3.0 Safety , tolerability efficacy PTL201 reduce multiple sclerosisassociated spasticityrelated symptom 3 . Moderate severe spasticity least two district upper and/or low limb 3 . Antispasticity agent ( ) and/or diseasemodifying medication maintain stable dose 30 day prior throughout study 4 . Patients able selfscore spasticity 5 . Absence clinical neuroradiological relapse least three month prior study entry 6 . Willingness ability provide write informed consent 7 . Willingness ability comply study requirement 8 . Inclusion criterion placebocontrolled treatment phase : No major protocol violation record patient responder phase least 20 % improvement sNRS 1 . Concomitant disease disorder spasticitylike symptom may influence subject 's level spasticity , medical history suggest relapse/remission likely recur study expect influence spasticity 2 . Currently use use cannabis cannabinoidbased medication within 30 day study entry unwilling abstain use duration study . 3 . Concurrent significant psychiatric , renal , hepatic , cardiovascular convulsive disorder 4 . History immediate family history schizophrenia , psychotic illness , severe personality disorder , significant psychiatric disorder depression relate MS/MSassociated spasticity . 5 . Any known suspected history substance abuse/dependence disorder ( include opiate abuse ) , current heavy alcohol consumption , current use illicit drug , current nonprescribed use prescription drug . 6 . Poorly control epilepsy recurrent seizure ( i.e. , one seizure past year ) . 7 . Known suspected hypersensitivity cannabinoids excipients study drug . 8 . Myocardial infarction clinically significant cardiac dysfunction within 12 month study entry cardiac disorder , opinion investigator , would put patient risk clinically significant arrhythmia myocardial infarction 9 . Female patient childbearing potential male patient whose partner childbearing potential , unless willing ensure partner use effective contraception throughout study three month thereafter 10 . Female patient pregnant , lactate , plan pregnancy course study within 3 month thereafter . 11 . Any significant disease disorder , , opinion investigator , participation study may either put patient risk may influence result study , patient 's ability participate study . 12 . Travel outside country plan study . 13 . Unwilling abstain donate blood study . 14 . Patients previously randomize cannabinoidbased clinical trial MS pain spasticity within 6 month study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>